Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 332
- Registration Number
- NCT03184870
- Locations
- 🇺🇸
Local Institution - 0004, Hackensack, New Jersey, United States
🇺🇸Local Institution - 0033, Boston, Massachusetts, United States
🇺🇸Local Institution - 0027, Rochester, Minnesota, United States
Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2017-06-27
- Target Recruit Count
- 200
- Registration Number
- NCT03175016
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Petr Kavan
- Target Recruit Count
- 20
- Registration Number
- NCT03167112
- Locations
- 🇨🇦
Jewish General Hospital, Montréal, Quebec, Canada
Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 32
- Registration Number
- NCT03146377
- Locations
- 🇭🇰
Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
- Conditions
- Interventions
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2021-06-21
- Target Recruit Count
- 20
- Registration Number
- NCT03142516
- Locations
- 🇪🇸
Hospital Sant Joan Despí-Moises Broggi, Sant Joan Despí, Barcelona, Spain
🇪🇸ICO L´Hospitalet de Llobregat - Hospital Durán i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital Universitario la Paz, Madrid, Spain
Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT03141034
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States
PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 16
- Registration Number
- NCT03139331
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸UCSF Benioff Children's Hospital, Oakland, Oakland, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 36
- Registration Number
- NCT03136055
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Jiangsu Cancer Institute & Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03126071
- Locations
- 🇨🇳
Nantong Tumor Hospital, Nantong, Jiangsu, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China
Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 37
- Registration Number
- NCT03116555
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.